<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803335</url>
  </required_header>
  <id_info>
    <org_study_id>08135-08-076</org_study_id>
    <nct_id>NCT00803335</nct_id>
  </id_info>
  <brief_title>The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse</brief_title>
  <official_title>The Effects of Local Vaginal Estrogen in Postmenopausal Women With Pelvic Organ Prolapse: A Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TriHealth Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TriHealth Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out how long it takes the vagina to respond to hormonal
      vaginal cream in women with pelvic organ prolapse (bulge in the vagina). It also will address
      the appropriate amount to use prior to vaginal repair of pelvic organ prolapse.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjective and objective vaginal health symptoms, validated pelvic floor questionnaires,
      cytology and histology will be analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaginal tissue samples obtained at the time of vaginal repair of pelvic organ prolapse will be analyzed for epithelial and subepithelial thickness, vascularity and inflammatory cells using standard H&amp;E stains.</measure>
    <time_frame>baseline and 2-12 weeks after treatment (at time of surgery)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaginal histology will be compared to validated pelvic floor quality of life questionnaires, vaginal health symptoms, vaginal health scoring, and vaginal cytology.</measure>
    <time_frame>baseline and 2-12 weeks after treatment (at time of surgery)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Pelvic Organ Prolapse</condition>
  <condition>Vaginal Atrophy</condition>
  <arm_group>
    <arm_group_label>Premarin cream 0.5gm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Application of 0.5gm of vaginal estrogen cream nightly until surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Premarin cream 1.0gm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Application of 1.0gm of vaginal estrogen cream nightly until surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No intervention</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Women in this arm will not apply any cream or moisturizers to the vagina until surgery, ie no intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal conjugated estrogen cream 0.5gm</intervention_name>
    <description>Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.</description>
    <arm_group_label>Premarin cream 0.5gm</arm_group_label>
    <other_name>Premarin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vaginal conjugated estrogen cream 1.0gm</intervention_name>
    <description>Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.</description>
    <arm_group_label>Premarin cream 1.0gm</arm_group_label>
    <other_name>Premarin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 45 years or older

          -  Postmenopausal (&gt;55 if natural menopause)

          -  Clinical atrophic vaginitis (at least mild atrophy)

          -  Pelvic organ prolapse(at least stage 2 or greater)

          -  Posthysterectomy

          -  Surgery date between 2-12 weeks after recruitment

        Exclusion Criteria:

          -  Uterus present

          -  Well-estrogenized appearing vagina

          -  Known or suspected history of breast carcinoma

          -  Hormone-dependent tumor

          -  Genital bleeding of unknown cause

          -  Acute thrombophlebitis or thromboembolic disorder associated with estrogen use

          -  Vaginal infection requiring treatment

          -  Allergy to estrogen or its constituents

          -  Any serious disease or chronic condition that would interfere with study compliance or
             preoperative surgical clearance.

          -  Use of exogenous corticosteroid or sex hormones (including homeopathic preparation)
             within the 8 weeks prior to recruitment

          -  Initiation or continuation of anticholinergic medication (which could bias the results
             of the pelvic floor questionnaires)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine M Vaccaro, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Good Samaritan Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trihealth (Good Samaritan Hospital, Bethesda North Hospital)</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <last_update_submitted>May 25, 2015</last_update_submitted>
  <last_update_submitted_qc>May 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pelvic organ prolapse</keyword>
  <keyword>vaginal atrophy</keyword>
  <keyword>atrophic vaginitis</keyword>
  <keyword>postmenopausal</keyword>
  <keyword>posthysterectomy</keyword>
  <keyword>vaginal health</keyword>
  <keyword>vaginal cytology</keyword>
  <keyword>vaginal maturity index</keyword>
  <keyword>vaginal histology</keyword>
  <keyword>quality of life questionnaires</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

